VEGFA and renal cell carcinoma: Knowledge relating to the consequences of disruption of VHL with stabilisation of HIF and consequent upregulation of factors such as vascular endothelial growth factor (VEGF) has been exploited with drugs targeting these pathways such as sorafenib, sunitinib and bevacizumab which have improved response rates and relapse-free survival in RCC (13).